marketcaparena
Search

    CELU

    Celularity Inc

    Company overview

    Market capitalization
    $40.52M
    Employees
    115
    Latest publication
    2026-09-29
    About Celularity Inc

    Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degenerative disease; and PDA-002 for treating multiple sclerosis, rheumatoid arthritis, stroke, and diabetic peripheral neuropathy. The company also produces, sells, and licenses products used in surgical and wound care markets, such as Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex; and collects, processes, and stores umbilical cord and placental blood and tissue after full-term pregnancies under the LifebankUSA brand. Celularity Inc. has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is headquartered in Florham Park, New Jersey.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Total Revenue4,104,000USD4,104,000USD5,284,000USD5,736,000USD18,132,000USD18,132,000USD9,296,000USD12,112,000USD
    Cost Of Revenue-4,452,000USD7,374,000USD2,018,000USD5,242,000USD7,343,000USD7,343,000USD3,883,000USD9,609,000USD
    Gross Profit8,556,000USD-3,270,000USD3,266,000USD494,000USD10,789,000USD10,789,000USD5,413,000USD2,503,000USD
    Research Development3,347,000USD3,347,000USD4,598,000USD3,352,000USD3,828,000USD3,828,000USD3,915,000USD108,072,000USD
    Unclassified Operating Expenses27,267,000USD7,751,000USD2,262,000USD——7,719,000USD—-131,908,000USD
    Total Operating Expenses30,614,000USD26,162,000USD16,166,000USD16,358,000USD20,069,000USD27,605,000USD16,940,000USD-10,812,000USD
    Operating Income-22,058,000USD-22,058,000USD-12,900,000USD-15,864,000USD-9,280,000USD-9,473,000USD-11,527,000USD13,315,000USD
    Interest Expense897,000USD897,000USD1,477,000USD1,943,000USD1,812,000USD1,812,000USD1,752,000USD663,000USD
    Income Before Tax-24,359,000USD-24,359,000USD-23,076,000USD-24,524,000USD-13,293,000USD-13,293,000USD-16,098,000USD9,557,000USD
    Income Tax Expense3,000USD—-3,000USD—13,489,000USD—-13,489,000USD10,000USD
    Net Income-24,362,000USD-24,362,000USD-23,073,000USD-24,524,000USD-13,293,000USD-13,293,000USD-16,098,000USD9,547,000USD
    Ebit-23,462,000USD—-21,599,000USD-22,581,000USD-9,473,000USD—-14,346,000USD-10,846,000USD
    Ebitda-21,659,000USD—-19,733,000USD-20,747,000USD-7,597,000USD—-12,452,000USD-8,550,000USD
    Depreciation And Amortization1,803,000USD—1,866,000USD1,834,000USD1,876,000USD—1,894,000USD2,296,000USD
    Total Other Income Expense Net-2,301,000USD-1,466,000USD-10,176,000USD-8,660,000USD-4,013,000USD-2,085,000USD-4,571,000USD-3,758,000USD
    Selling General Administrative—15,064,000USD9,306,000USD12,634,000USD16,035,000USD16,058,000USD12,650,000USD13,024,000USD
    Interest Income—62,000USD62,000USD62,000USD76,000USD77,000USD77,000USD67,000USD
    Net Interest Income—-835,000USD-1,415,000USD-1,881,000USD-2,361,000USD-1,735,000USD-1,675,000USD-1,485,000USD
    Tax Provision—3,000USD0USD0USD0USD0USD0USD0USD
    Net Income From Continuing Ops—-24,362,000USD-23,076,000USD-24,524,000USD-19,754,000USD-13,293,000USD-16,098,000USD-6,488,000USD
    Reconciled Depreciation—1,803,000USD1,824,000USD1,834,000USD1,834,000USD1,876,000USD1,894,000USD1,996,000USD
    Selling And Marketing Expenses————23,000USD———
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Revenue26,550,000USD54,220,000USD22,771,000USD17,975,000USD21,335,000USD14,278,000USD21,147,000USD17,554,000USD
    Cost Of Revenue6,362,000USD14,989,000USD16,016,000USD19,665,000USD9,653,000USD4,932,000USD6,324,000USD6,555,000USD
    Gross Profit20,188,000USD39,231,000USD6,755,000USD-1,690,000USD11,682,000USD9,346,000USD14,823,000USD10,999,000USD
    Research Development15,025,000USD17,386,000USD30,465,000USD78,363,000USD88,353,000USD52,707,000USD46,051,000USD29,063,000USD
    Selling General Administrative51,266,000USD58,620,000USD50,576,000USD65,858,000USD71,089,000USD30,572,000USD40,633,000USD—
    Unclassified Operating Expenses15,205,000USD1,560,000USD18,209,000USD-120,311,000USD-38,701,000USD77,228,000USD191,110,000USD-29,061,902USD
    Total Operating Expenses81,496,000USD77,589,000USD99,250,000USD23,910,000USD120,741,000USD161,271,000USD278,952,000USD1,098USD
    Operating Income-61,308,000USD-38,358,000USD-76,479,000USD-25,600,000USD-109,059,000USD-151,925,000USD-264,129,000USD-1,098USD
    Interest Income262,000USD331,000USD320,000USD365,000USD332,000USD370,000USD——
    Interest Expense6,754,000USD6,264,000USD3,015,000USD3,171,000USD3,171,000USD2,354,000USD3,745,540USD0USD
    Net Interest Income-6,492,000USD-5,933,000USD-2,695,000USD365,000USD-2,839,000USD-1,984,000USD——
    Income Before Tax-91,713,000USD-57,892,000USD-196,285,000USD14,205,000USD-100,098,000USD-212,933,000USD-267,994,000USD-1,098USD
    Income Tax Expense3,000USD10,000USD—13,000USD20,000USD-4,700,000USD-56,113,000USD21,302,000USD
    Tax Provision3,000USD0USD10,000USD13,000USD20,000USD-4,700,000USD——
    Net Income-91,800,000USD-57,892,000USD-196,295,000USD14,192,000USD-100,118,000USD-208,233,000USD-211,881,000USD-1,098USD
    Net Income From Continuing Ops-91,716,000USD-57,892,000USD-196,295,000USD14,192,000USD-100,118,000USD-49,260,297USD2,512,971USD—
    Ebit-84,959,000USD-51,628,000USD—-148,267,000USD-96,927,000USD-210,579,000USD-77,162,000USD-4,791,098USD
    Ebitda-77,664,000USD-43,706,000USD—-138,831,000USD-88,110,000USD-202,405,000USD-70,976,000USD-1,098USD
    Depreciation And Amortization7,295,000USD7,922,000USD—9,436,000USD8,817,000USD8,174,000USD6,186,000USD4,790,000USD
    Reconciled Depreciation7,295,000USD7,922,000USD9,324,000USD9,436,000USD8,817,000USD8,174,000USD——
    Total Other Income Expense Net-30,405,000USD-19,534,000USD-117,111,000USD39,805,000USD8,961,000USD-61,008,000USD-3,865,000USD2USD
    Selling And Marketing Expenses—23,000USD———764,000USD1,158,000USD—
    Net Income Applicable To Common Shares———14,192,000USD-100,118,000USD-49,260,297USD-211,881,000USD-13,375,000USD
    Non Operating Income Net Other—————-44,848,693USD3,745,540USD—
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Total Assets107,329,000USD107,329,000USD114,239,000USD120,283,000USD132,682,000USD132,682,000USD128,840,000USD143,889,000USD
    Intangible Assets7,756,000USD7,756,000USD8,132,000USD8,508,000USD9,248,000USD9,248,000USD9,624,000USD11,001,000USD
    Other Current Assets920,000USD222,000USD1,208,000USD838,000USD857,000USD261,000USD1,636,000USD1,695,000USD
    Total Liab145,391,000USD145,391,000USD134,333,000USD145,780,000USD123,845,000USD123,845,000USD111,560,000USD102,929,000USD
    Total Stockholder Equity-38,062,000USD-38,062,000USD-20,094,000USD-25,497,000USD8,837,000USD8,837,000USD17,280,000USD40,960,000USD
    Other Current Liab35,079,000USD6,925,000USD29,420,999USD34,379,000USD20,492,000USD1,090,000USD14,466,000USD11,080,000USD
    Common Stock3,000USD—3,000USD2,000USD2,000USD—2,000USD19,000USD
    Retained Earnings-991,483,000USD-991,483,000USD-967,101,000USD-944,025,000USD-899,683,000USD-899,683,000USD-886,390,000USD-841,791,000USD
    Good Will7,347,000USD7,347,000USD7,347,000USD7,347,000USD7,347,000USD7,347,000USD7,347,000USD7,347,000USD
    Cash6,175,000USD6,175,000USD120,000USD863,000USD738,000USD738,000USD133,000USD227,000USD
    Cash And Short Term Investments6,175,000USD—120,000USD863,000USD738,000USD—133,000USD227,000USD
    Total Current Assets12,319,000USD12,319,000USD10,596,000USD17,263,000USD20,561,000USD20,561,000USD14,502,000USD19,793,000USD
    Total Current Liabilities80,759,000USD80,759,000USD65,313,999USD69,227,000USD53,680,000USD53,680,000USD76,169,000USD67,298,000USD
    Current Deferred Revenue5,255,000USD—5,584,000USD3,503,000USD3,531,000USD—3,693,000USD2,834,000USD
    Net Debt34,726,000USD7,828,000USD66,642,000USD69,291,000USD68,098,000USD41,550,000USD68,928,000USD65,190,000USD
    Short Term Debt14,003,000USD—5,722,000USD6,945,000USD6,361,000USD—42,610,000USD39,240,000USD
    Short Long Term Debt Total40,901,000USD—66,762,000USD70,154,000USD68,836,000USD—69,061,000USD65,417,000USD
    Net Receivables4,653,000USD4,653,000USD6,705,000USD11,152,000USD13,557,000USD13,557,000USD8,770,000USD12,118,000USD
    Inventory571,000USD571,000USD2,563,000USD4,410,000USD5,409,000USD5,409,000USD3,963,000USD5,753,000USD
    Accounts Payable26,422,000USD26,422,000USD24,587,000USD24,400,000USD23,296,000USD23,296,000USD15,400,000USD14,144,000USD
    Property Plant Equipment Net66,517,000USD66,517,000USD67,967,000USD69,441,000USD72,430,000USD72,430,000USD74,073,000USD78,818,000USD
    Common Stock Shares Outstanding25,598,586shares28,837,787shares26,347,818shares24,020,193shares22,352,482shares22,546,671shares21,976,339shares19,378,192shares
    Non Current Assets Total95,010,000USD95,010,000USD103,643,000USD103,020,000USD112,121,000USD112,121,000USD114,338,000USD124,096,000USD
    Non Current Liabilities Total64,632,000USD64,632,000USD69,019,000USD76,553,000USD70,165,000USD70,165,000USD35,391,000USD35,631,000USD
    Non Currrent Assets Other13,390,000USD13,390,000USD7,172,000USD7,651,000USD12,857,000USD23,096,000USD13,131,000USD26,930,000USD
    Unclassified Non Current Liabilities64,632,000USD31,254,000USD67,337,000USD38,375,000USD31,984,000USD32,545,000USD33,502,000USD33,738,000USD
    Unclassified Equity953,418,000USD953,418,000USD947,001,000USD918,527,000USD908,521,000USD908,518,000USD903,668,000USD882,730,000USD
    Capital Stock—3,000USD3,000USD2,000USD2,000USD2,000USD2,000USD2,000USD
    Short Long Term Debt—14,003,000USD4,284,000USD6,945,000USD6,653,000USD6,361,000USD42,610,000USD40,999,000USD
    Property Plant Equipment Gross—105,187,000USD105,210,000USD105,236,000USD105,265,000USD105,297,000USD106,020,000USD106,058,000USD
    Non Current Liabilities Other—33,378,000USD1,682,000USD1,686,000USD1,689,000USD1,693,000USD1,889,000USD1,893,000USD
    Net Working Capital—-68,440,000USD-54,718,000USD-51,964,000USD-36,610,000USD-33,119,000USD-61,667,000USD-50,169,000USD
    Unclassified Current Liabilities—33,409,000USD-4,284,000USD-6,945,000USD-6,653,000USD22,933,000USD-42,610,000USD-40,999,000USD
    Long Term Investments——2,890,000USD—————
    Unclassified Non Current Assets——10,135,000USD10,073,000USD10,239,000USD—10,163,000USD—
    Long Term Debt———36,492,000USD36,492,000USD35,927,000USD——
    Accumulated Other Comprehensive Income———-3,000USD-5,000USD—-2,000USD0USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets107,329,000USD132,682,000USD143,889,000USD401,066,000USD414,128,000USD431,008,000USD521,495,000USD24,707USD
    Intangible Assets7,756,000USD9,248,000USD11,001,000USD120,994,000USD123,187,000USD125,379,000USD271,469,000USD393,712,000USD
    Other Current Assets920,000USD857,000USD329,000USD7,262,000USD2,000USD7,449,000USD2,368,000USD2,883,000USD
    Total Liab145,391,000USD123,845,000USD102,929,000USD202,165,000USD314,710,000USD412,295,000USD383,633,000USD150,555USD
    Total Stockholder Equity-38,062,000USD8,837,000USD40,960,000USD198,901,000USD99,418,000USD18,713,000USD137,862,000USD-125,847USD
    Other Current Liab35,079,000USD20,492,000USD2,448,000USD16,402,000USD11,661,000USD13,159,000USD20,597,234USD-5,117,445USD
    Common Stock3,000USD2,000USD—15,000USD12,000USD1,000USD1,000USD863USD
    Capital Stock3,000USD2,000USD19,000USD15,000USD12,000USD1,000USD——
    Retained Earnings-991,483,000USD-899,683,000USD-841,791,000USD-645,496,000USD-663,681,000USD-563,563,000USD-355,330,000USD-1,098USD
    Good Will7,347,000USD7,347,000USD7,347,000USD119,694,000USD123,304,000USD123,304,000USD127,068,000USD130,642,000USD
    Cash6,175,000USD738,000USD227,000USD13,966,000USD37,240,000USD54,311,000USD28,128,000USD24,707USD
    Cash And Short Term Investments6,175,000USD738,000USD—13,966,000USD37,240,000USD54,311,000USD28,128,000USD24,707USD
    Total Current Assets12,319,000USD20,561,000USD19,793,000USD33,502,000USD37,240,000USD72,160,000USD36,806,000USD24,707USD
    Total Current Liabilities80,759,000USD53,680,000USD67,298,000USD62,088,000USD26,225,000USD26,677,000USD20,635,000USD150,555USD
    Current Deferred Revenue5,255,000USD3,531,000USD—2,273,000USD2,196,000USD5,120,000USD——
    Net Debt34,726,000USD68,098,000USD39,013,000USD51,622,000USD-6,104,000USD-23,669,000USD-66,000USD125,293USD
    Short Term Debt14,003,000USD6,361,000USD—37,603,000USD3,051,000USD3,008,000USD——
    Short Long Term Debt14,003,000USD6,361,000USD39,240,000USD37,603,000USD————
    Short Long Term Debt Total40,901,000USD68,836,000USD—65,588,000USD31,136,000USD30,642,000USD28,062,000USD150,000USD
    Net Receivables4,653,000USD13,557,000USD10,046,000USD6,966,000USD5,233,000USD6,550,000USD3,078,000USD3,919,000USD
    Inventory571,000USD5,409,000USD5,753,000USD5,308,000USD9,549,000USD3,850,000USD3,232,000USD3,536,000USD
    Accounts Payable26,422,000USD23,296,000USD14,144,000USD5,810,000USD9,317,000USD5,390,000USD18,883USD5,268,000USD
    Property Plant Equipment Net66,517,000USD72,430,000USD78,818,000USD88,715,000USD90,625,000USD90,077,000USD66,387,000USD4,011,000USD
    Property Plant Equipment Gross105,187,000USD105,297,000USD106,096,000USD109,046,000USD105,404,000USD97,163,000USD——
    Common Stock Shares Outstanding25,598,586shares21,890,518shares19,378,164shares14,983,000shares12,726,133shares1,841,791shares2,387,283shares3,593,750shares
    Non Current Assets Total95,010,000USD112,121,000USD124,096,000USD367,564,000USD376,888,000USD358,847,999USD484,689,000USD532,170,000USD
    Non Current Liabilities Total64,632,000USD70,165,000USD35,631,000USD140,077,000USD288,485,000USD385,618,000USD362,998,000USD—
    Non Current Liabilities Other33,378,000USD1,693,000USD1,900,000USD106,266,000USD232,557,000USD74,612,500USD10,812,500USD—
    Non Currrent Assets Other13,390,000USD12,857,000USD26,930,000USD23,316,000USD39,772,000USD4,885,999USD-271,236,653USD3,805,000USD
    Net Working Capital-68,440,000USD-33,119,000USD-47,505,000USD-28,586,000USD32,875,000USD45,483,000USD——
    Unclassified Current Liabilities-14,003,000USD-6,361,000USD11,466,000USD-37,603,000USD———-5,117,445USD
    Unclassified Non Current Liabilities31,254,000USD32,545,000USD33,731,000USD-78,281,000USD-204,472,000USD-46,979,102USD17,249,500USD—
    Unclassified Equity953,415,000USD908,521,000USD882,732,000USD844,358,000USD1,177,203,000USD1,132,387,000USD1,216,867,790USD—
    Long Term Debt—35,927,000USD——————
    Accumulated Other Comprehensive Income—-5,000USD—9,000USD-414,128,000USD-550,113,000USD-723,676,790USD-149,750USD
    Unclassified Non Current Assets—10,239,000USD—14,845,000USD-17,912,000USD-4,886,000USD——
    Unclassified Current Assets——3,438,000USD—-14,784,000USD——-10,338,000USD
    Other Liab———112,092,000USD260,400,000USD357,984,000USD334,936,000USD325,956,000USD
    Net Tangible Assets———-41,787,000USD-147,073,000USD214,133,459USD-725,957,000USD-643,669,000USD
    Other Assets————17,912,000USD20,088,000USD19,765,000USD-532,170,000USD
    Deferred Long Term Liab—————602USD——
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Net Income-24,362,000USD-24,362,000USD-23,076,000USD-24,524,000USD-13,293,000USD-13,293,000USD-16,097,999USD9,547,000USD
    Depreciation1,803,000USD1,803,000USD1,824,000USD1,834,000USD1,876,000USD1,876,000USD1,894,000USD2,296,000USD
    Stock Based Compensation3,252,000USD3,252,000USD2,041,000USD2,448,000USD3,099,000USD3,099,000USD2,672,000USD3,575,000USD
    Other Non Cash Items6,342,000USD508,000USD8,364,000USD4,484,000USD163,000USD1,152,000USD2,666,999USD13,336,000USD
    Change To Account Receivables548,000USD548,000USD4,545,000USD3,808,000USD-5,022,000USD-5,022,000USD4,786,000USD-6,709,000USD
    Change To Inventory1,725,000USD1,725,000USD2,307,000USD3,664,000USD631,000USD631,000USD503,000USD740,000USD
    Change In Working Capital7,862,000USD7,862,000USD6,688,000USD14,759,000USD9,749,000USD9,749,000USD8,721,000USD-33,095,000USD
    Total Cash From Operating Activities-5,103,000USD-5,103,000USD-4,159,000USD-998,999USD1,594,000USD1,594,000USD-144,000USD-4,341,000USD
    Capital Expenditures0USD0USD-56,000USD0USD-56,000USD-56,000USD-35,000USD-580,000USD
    Free Cash Flow-5,103,000USD-5,103,000USD-4,159,000USD-999,000USD1,538,000USD1,538,000USD-179,000USD-4,921,000USD
    Total Cash From Financing Activities11,220,000USD11,220,000USD3,478,000USD1,631,000USD643,000USD643,000USD-79,000USD-14,000USD
    Change In Cash6,117,000USD6,117,000USD-743,000USD570,000USD681,000USD681,000USD-258,000USD-4,935,000USD
    Begin Period Cash Flow10,255,000USD10,255,000USD863,000USD293,000USD10,296,000USD10,296,000USD10,554,000USD15,098,000USD
    End Period Cash Flow16,372,000USD16,372,000USD120,000USD863,000USD10,977,000USD10,977,000USD10,296,000USD10,163,000USD
    Other Cashflows From Financing Activities-772,000USD—469,000USD656,000USD54,000USD—-73,000USD-14,000USD
    Unclassified Financing Cash Flow11,992,000USD17,075,000USD-3,268,000USD—-1,829,000USD———
    Net Borrowings—-6,820,000USD6,776,000USD-35,000USD-42,000USD589,000USD-6,000USD—
    Dividends Paid—0USD-64,000USD—————
    Issuance Of Capital Stock—965,000USD-435,000USD1,010,000USD2,460,000USD0USD0USD0USD
    Unclassified Operating Cash Flow—5,834,000USD——————
    Investments——0USD0USD0USD-1,556,000USD-35,000USD2,144,000USD
    Total Cashflows From Investing Activities——2,890,000USD—-1,556,000USD—-35,000USD-580,000USD
    Other Cashflows From Investing Activities——56,000USD-56,000USD-1,500,000USD—2,175,000USD-3,000,000USD
    Unclassified Investing Cash Flow——2,890,000USD———-2,140,000USD—
    Sale Purchase Of Stock———————-14,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Net Income-91,716,000USD-57,892,000USD-196,295,000USD14,192,000USD-100,118,000USD-208,233,000USD5,878,770USD-13,375,000USD
    Depreciation7,295,000USD7,922,000USD9,324,000USD9,436,000USD8,817,000USD8,174,000USD6,186,000USD4,790,000USD
    Stock Based Compensation10,378,000USD11,569,000USD15,017,000USD15,856,000USD40,010,000USD4,371,000USD3,668,000USD4,501,000USD
    Other Non Cash Items27,192,000USD9,800,000USD-92,314,000USD-161,907,000USD-46,369,000USD137,373,000USD-7,111,339USD-54,543,000USD
    Change To Account Receivables7,551,000USD-3,968,000USD-6,827,000USD-3,584,000USD-1,909,000USD1,652,000USD134,000USD-2,287,000USD
    Change To Inventory10,246,000USD6,284,000USD-865,000USD-16,891,000USD-6,422,000USD-643,000USD-1,708,000USD-3,403,000USD
    Change In Working Capital33,594,000USD22,200,000USD3,252,000USD-15,453,000USD-11,083,000USD3,604,000USD136,389USD-1,342,000USD
    Total Cash From Operating Activities-13,254,000USD-6,401,000USD-38,685,000USD-137,876,000USD-110,096,000USD-63,193,000USD-1,097,833USD-543USD
    Capital Expenditures0USD-161,000USD-4,048,000USD-5,236,000USD-6,203,000USD-27,834,000USD-3USD-1,918,000USD
    Free Cash Flow-13,254,000USD-6,562,000USD-42,733,000USD-143,112,000USD-116,299,000USD-91,027,000USD-1,097,830USD-1,918,543USD
    Net Borrowings-121,000USD-13,898,000USD-14,811,000USD85,691,000USD0USD—-150,000USD—
    Total Cash From Financing Activities18,649,000USD6,701,000USD24,094,000USD119,838,000USD98,562,000USD102,014,000USD288,839,133USD25,250USD
    Dividends Paid-5,900,000USD0USD—-39,068,000USD————
    Issuance Of Capital Stock4,000,000USD6,000,000USD21,886,000USD36,519,000USD83,400,000USD102,535,000USD——
    Change In Cash5,395,000USD814,000USD-18,639,000USD-23,274,000USD-17,437,000USD26,006,000USD892,300USD-31,160,293USD
    Begin Period Cash Flow10,977,000USD10,163,000USD28,802,000USD52,076,000USD69,513,000USD43,507,000USD24,707USD31,185,000USD
    End Period Cash Flow16,372,000USD10,977,000USD10,163,000USD28,802,000USD52,076,000USD69,513,000USD917,007USD24,707USD
    Other Cashflows From Financing Activities255,000USD-459,000USD—27,264,000USD20,162,000USD102,270,000USD-150,000USD250USD
    Unclassified Financing Cash Flow20,415,000USD15,058,000USD17,019,000USD46,083,000USD78,400,000USD—282,650,000USD—
    Investments—514,000USD-4,048,000USD-5,236,000USD-5,903,000USD-137,500USD-287,500,000USD—
    Total Cashflows From Investing Activities—514,000USD—-5,236,000USD-5,903,000USD-12,815,000USD-286,849,000USD-31,185,000USD
    Other Cashflows From Investing Activities—2,175,000USD—300,000USD300,000USD15,019,000USD651,000USD14,000USD
    Unclassified Investing Cash Flow—-2,014,000USD—4,936,000USD5,903,000USD——-29,281,000USD
    Unclassified Operating Cash Flow——222,331,000USD—-1,353,000USD-8,482,000USD-9,855,653USD59,968,457USD
    Change To Liabilities———-2,948,000USD-5,375,000USD3,180,778USD-1,580,000USD1,664,000USD
    Sale Purchase Of Stock———-132,000USD0USD-256,000USD6,489,133USD—
    Cash And Cash Equivalents Changes—————-602,311USD892,300USD—
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    FY 2025Yearly · 2025-12-31ProductLicense Royalty And Other7,943,000USD0001493152-26-020424
    FY 2025Yearly · 2025-12-31ProductProduct13,175,000USD0001493152-26-020424
    FY 2025Yearly · 2025-12-31ProductServices5,432,000USD0001493152-26-020424
    Q4 2025Quarterly · 2025-12-31SegmentBiobanking1,301,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31SegmentCell Therapy1,192,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31SegmentDegenerative Disease1,611,000USDLegacy provider
    FY 2025Yearly · 2025-12-31SegmentBiobanking5,432,000USD0001493152-26-020424
    FY 2025Yearly · 2025-12-31SegmentCell Therapy3,807,000USD0001493152-26-020424
    FY 2025Yearly · 2025-12-31SegmentDegenerative Disease17,311,000USD0001493152-26-020424
    Q3 2025Quarterly · 2025-09-30SegmentBiobanking1,448,000USD0001493152-25-023467
    Q3 2025Quarterly · 2025-09-30SegmentCell Therapy1,592,000USD0001493152-25-023467
    Q3 2025Quarterly · 2025-09-30SegmentDegenerative Disease2,244,000USD0001493152-25-023467
    Q2 2025Quarterly · 2025-06-30SegmentBiobanking1,275,000USD0001641172-25-026067
    Q2 2025Quarterly · 2025-06-30SegmentCell Therapy759,000USD0001641172-25-026067
    Q2 2025Quarterly · 2025-06-30SegmentDegenerative Disease3,702,000USD0001641172-25-026067
    Q1 2025Quarterly · 2025-03-31SegmentBiobanking1,408,000USD0001641172-25-026056
    Q1 2025Quarterly · 2025-03-31SegmentCell Therapy264,000USD0001641172-25-026056
    Q1 2025Quarterly · 2025-03-31SegmentDegenerative Disease9,754,000USD0001641172-25-026056
    FY 2024Yearly · 2024-12-31ProductLicense Royalty And Other13,744,000USD0001493152-26-020424
    FY 2024Yearly · 2024-12-31ProductProduct35,336,000USD0001493152-26-020424
    FY 2024Yearly · 2024-12-31ProductServices5,140,000USD0001493152-26-020424
    FY 2024Yearly · 2024-12-31SegmentBiobanking5,140,000USD0001493152-26-020424
    FY 2024Yearly · 2024-12-31SegmentCell Therapy688,000USD0001493152-26-020424
    FY 2024Yearly · 2024-12-31SegmentDegenerative Disease48,392,000USD0001493152-26-020424
    Q4 2024Quarterly · 2024-12-31ProductLicense Royalty And Other7,712,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31ProductProduct9,137,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31ProductServices1,283,000USDLegacy provider
    Q3 2024Quarterly · 2024-09-30SegmentBiobanking1,292,000USD0001493152-25-023467
    Q3 2024Quarterly · 2024-09-30SegmentDegenerative Disease8,004,000USD0001493152-25-023467
    Q3 2024Quarterly · 2024-09-30ProductLicense Royalty And Other4,611,000USD0000950170-24-133799
    Q3 2024Quarterly · 2024-09-30ProductProduct3,393,000USD0000950170-24-133799
    Q3 2024Quarterly · 2024-09-30ProductServices1,292,000USD0000950170-24-133799
    Q2 2024Quarterly · 2024-06-30SegmentBiobanking1,278,000USD0001641172-25-026067
    Q2 2024Quarterly · 2024-06-30SegmentDegenerative Disease10,833,000USD0001641172-25-026067
    Q2 2024Quarterly · 2024-06-30ProductLicense Royalty And Other870,000USD0000950170-24-122493
    Q2 2024Quarterly · 2024-06-30ProductProduct9,963,000USD0000950170-24-122493
    Q2 2024Quarterly · 2024-06-30ProductServices1,278,000USD0000950170-24-122493
    Q1 2024Quarterly · 2024-03-31SegmentBiobanking1,287,000USD0001641172-25-026056
    Q1 2024Quarterly · 2024-03-31SegmentDegenerative Disease13,394,000USD0001641172-25-026056
    Q1 2024Quarterly · 2024-03-31ProductLicense Royalty And Other551,000USD0000950170-24-115082
    Q1 2024Quarterly · 2024-03-31ProductProduct12,843,000USD0000950170-24-115082
    Q1 2024Quarterly · 2024-03-31ProductServices1,287,000USD0000950170-24-115082
    FY 2023Yearly · 2023-12-31ProductLicense Royalty And Other4,181,000USD0001641172-25-009319
    FY 2023Yearly · 2023-12-31ProductProduct13,149,000USD0001641172-25-009319
    FY 2023Yearly · 2023-12-31ProductServices5,441,000USD0001641172-25-009319
    Q4 2023Quarterly · 2023-12-31SegmentBiobanking1,379,000USDLegacy provider
    Q4 2023Quarterly · 2023-12-31SegmentDegenerative Disease10,733,000USDLegacy provider
    FY 2023Yearly · 2023-12-31SegmentBiobanking5,441,000USD0001641172-25-009319
    FY 2023Yearly · 2023-12-31SegmentDegenerative Disease17,330,000USD0001641172-25-009319
    Q4 2023Quarterly · 2023-12-31ProductLicense Royalty And Other1,217,000USDLegacy provider
    Q4 2023Quarterly · 2023-12-31ProductProduct9,516,000USDLegacy provider
    Q4 2023Quarterly · 2023-12-31ProductServices1,379,000USDLegacy provider
    Q3 2023Quarterly · 2023-09-30ProductLicense Royalty And Other675,000USD0000950170-24-133799
    Q3 2023Quarterly · 2023-09-30ProductProduct1,684,000USD0000950170-24-133799
    Q3 2023Quarterly · 2023-09-30ProductServices1,427,000USD0000950170-24-133799
    Q2 2023Quarterly · 2023-06-30ProductLicense Royalty And Other754,000USD0000950170-24-122493
    Q2 2023Quarterly · 2023-06-30ProductProduct906,000USD0000950170-24-122493
    Q2 2023Quarterly · 2023-06-30ProductServices1,278,000USD0000950170-24-122493
    Q1 2023Quarterly · 2023-03-31ProductLicense Royalty And Other1,535,000USD0000950170-24-115082
    Q1 2023Quarterly · 2023-03-31ProductProduct1,043,000USD0000950170-24-115082
    Q1 2023Quarterly · 2023-03-31ProductServices1,357,000USD0000950170-24-115082
    FY 2022Yearly · 2022-12-31ProductLicense Royalty And Other8,714,000USD0000950170-24-087886
    FY 2022Yearly · 2022-12-31ProductProduct3,749,000USD0000950170-24-087886
    FY 2022Yearly · 2022-12-31ProductServices5,512,000USD0000950170-24-087886
    FY 2022Yearly · 2022-12-31SegmentBiobanking5,512,000USD0000950170-24-087886
    FY 2022Yearly · 2022-12-31SegmentDegenerative Disease12,463,000USD0000950170-24-087886
    FY 2021Yearly · 2021-12-31ProductLicense Royalty And Other12,012,000USD0000950170-23-011440
    FY 2021Yearly · 2021-12-31ProductProduct3,801,000USD0000950170-23-011440
    FY 2021Yearly · 2021-12-31ProductServices5,522,000USD0000950170-23-011440
    FY 2021Yearly · 2021-12-31SegmentBiobanking5,522,000USD0000950170-23-011440
    FY 2021Yearly · 2021-12-31SegmentDegenerative Disease15,813,000USD0000950170-23-011440
    FY 2020Yearly · 2020-12-31ProductLicense Royalty And Other1,868,000USD0001564590-22-013004
    FY 2020Yearly · 2020-12-31ProductProduct6,854,000USD0001564590-22-013004
    FY 2020Yearly · 2020-12-31ProductServices5,556,000USD0001564590-22-013004
    FY 2020Yearly · 2020-12-31SegmentBiobanking5,556,000USD0001564590-22-013004
    FY 2020Yearly · 2020-12-31SegmentDegenerative Disease8,722,000USD0001564590-22-013004

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.